The RiceX Company (OTC:RICX) announced today that it has been issued US Patent No. 6,126,943.

The title of the patent is, METHOD FOR TREATING HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, AND ATHEROSCLEROSIS. The patent contains 26 claims describing the treatment method for reducing mammalian serum total cholesterol, LDL cholesterol, apolipoprotein B and triglyceride levels, by ingesting stabilized rice bran derivatives named RiceX Solubles and RiceX Fiber Concentrate. Efficacy of the RiceX products was demonstrated during clinical testing and review completed by Advanced Medical Research Center at Madison, Wisconsin. The patent is especially important to the Company in its efforts to market nutritionally dense, natural whole food ingredients to its food supplement and nutraceutical customers.

RiceX has commercialized the process and currently markets the products under the trade names RiceX Solubles and RiceX Fiber Concentrate. Both products are distributed and sold through an exclusive patent rights agreement with NutraStar Incorporated

Dan McPeak, Sr., Chairman and CEO of The RiceX Company, commented, "The new RiceX patent demonstrates our commitment to producing the most nutritious and healthful products available to the marketplace. We are excited with the prospects of RiceX Solubles and Fiber Concentrate being used as a safe and wholesome treatment method to reduce cholesterol and triglycerides in humans."

The RiceX Company manufactures and distributes nutritionally dense foods and food ingredients made from its stabilized rice bran that add significant nutritional benefits to food and consumer products. The company believes it is the only company in the world that can deliver all natural, nutritionally dense stabilized rice bran products with the shelf life and nutritional profile demanded by most commercial users.

For more information call The RiceX Company at 916-933-3060.

`Safe harbor' statements under the Private Securities Litigation Reform Act of 1995: This release contains forward looking statements that are subject to risks and uncertainties, including, but not limited to, the impact of the competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.